ClinicalTrials.Veeva

Menu

Effectiveness of Cognitive-Affective Behavior Therapy for the Treatment of Somatization Disorder

Rutgers The State University of New Jersey logo

Rutgers The State University of New Jersey

Status and phase

Completed
Phase 2

Conditions

Somatization Disorder

Treatments

Behavioral: Cognitive-Affective Behavior Therapy
Behavioral: Augmented Standard Medical Care

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00149760
R21MH066831 (U.S. NIH Grant/Contract)
DAHBR 96-BHC

Details and patient eligibility

About

This study will examine the long-term effect of cognitive-affective behavior therapy on the physical symptoms, functioning, and health care utilization of people with somatization disorder.

Full description

Somatization disorder is a syndrome characterized by the presence of multiple medically unexplained physical symptoms. It often results in substantial functional impairment and the need for extensive medical treatment. Neither pharmacological nor psychosocial treatments for the disease have demonstrated clinical success. People with somatization disorder may benefit from a treatment that integrates emotion-centered strategies into cognitive behavioral therapy. The long-term effectiveness of this treatment has not been established, however. This study will examine the long-term effect of cognitive-affective behavior therapy on the physical symptoms, functioning, and health care utilization of people with somatization disorder.

Participants in this open-label study will be randomly assigned to receive either cognitive-affective behavior therapy (CABT) or standard medical care that is augmented by a psychiatric consultation. Treatment will last 4 months. Assessments of somatic symptomatology, functional impairment, and health care costs will occur at screening, baseline (1 to 2 weeks after screening), and 4, 10, and 16 months after baseline. The visits at 10 and 16 months post-baseline will assess specifically the long-term efficacy of the treatment.

Enrollment

88 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Meets DSM-IV criteria for somatization disorder
  • Available for follow-up over the ensuing 18 months
  • English-speaking

Exclusion criteria

  • Meets DSM-IV criteria for a psychotic disorder, organic brain syndrome, or psychoactive substance dependence (Other psychiatric comorbidity is not exclusionary)
  • Active suicidal ideation
  • Unstable major medical condition
  • Plans to engage in additional psychotherapy during the first 6 months after enrollment
  • Current use of any medication that has not been stabilized for the previous 2 months

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

88 participants in 2 patient groups

Augmented Standard Medical Care
Active Comparator group
Description:
Participants will receive standard medical care augmented by a psychiatric consultation letter sent to the participants' primary care physician.
Treatment:
Behavioral: Augmented Standard Medical Care
Cognitive-Affective Behavior Therapy
Experimental group
Description:
Participants will receive individually administered cognitive-affective behavior therapy as well as augmented standard medical care.
Treatment:
Behavioral: Cognitive-Affective Behavior Therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems